glp-1 obesity drug news today oct 2025 2024 was a record year for trials and is already poised to take over ADA '26: Lilly's dominance, Pfizer's
Description
While adult obesity rates have driven commercial focus, childhood obesity has reached epidemic proportions globally, with limited therapeutic options available for younger patients
GLP-1 medications can interact with this step in a specific way
Personalized, data-guided goals : Your wellness journey is unique, and your biometric data is the key
Altywaiq, A
It can also affect how nutrients and water are absorbed, contributing to loose stools
Importantly, patients prefer, and are more likely to adhere to, an oral drug regimen versus an injectable alternative ( 11 )
